SCHEMBL1104576

SCHEMBL1104576

COC1C(OC(C)=O)C2OC1C1C(=O)N(c3ccc(C)cc3)C(=O)C21

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
CACNA1B Q00975 2/20 0.44
APBA1 Q02410 2/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 1/20 0.44
ATM Q13315 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.40
F2 P00734 1/20 0.38
ELANE P08246 1/20 0.38
CTSG P08311 1/20 0.38
CMA1 P23946 1/20 0.38
CTRC Q99895 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.37
LMNA P02545 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1104603 0.77 ATM (0.54) ALDH1A1CACNA1BAPBA1MAPTATM
SCHEMBL13325754 0.75 ATM (0.39) ALDH1A1CACNA1BAPBA1MAPTHPGD
SCHEMBL1104577 0.75 ALDH1A1 (0.50) ALDH1A1CACNA1BAPBA1MAPTHPGD
SCHEMBL1104567 0.74 ATM (0.40) ALDH1A1MAPTATMTP53GAA
SCHEMBL13325944 0.72 POLB (0.33)
SCHEMBL1104566 0.71 ATM (0.48) ALDH1A1CACNA1BAPBA1MAPTHPGD
SCHEMBL1104587 0.71 POLB (0.33) TSHR
SCHEMBL12605364 0.69 TP53 (0.65) ALDH1A1CACNA1BAPBA1MAPTHPGD
SCHEMBL18086651 0.66 TP53 (0.47) ALDH1A1CACNA1BAPBA1MAPTHPGD
SCHEMBL1104580 0.66 ATM (0.69) ALDH1A1CACNA1BAPBA1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541599-B2 Supports for oligomer synthesis ISIS PHARMACEUTICALS, INC. (US) 2013-09-24 US disclosed
US-20120165547-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2012-06-28 US disclosed
US-8153725-B2 Supports for oligomer synthesis ISIS PHARMACEUTICALS, INC (US) 2012-04-10 US disclosed
US-20100234528-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-7576119-B2 Supports for oligomer synthesis ISIS PHARMACEUTICALS, INC. (US) 2009-08-18 US disclosed
US-20080021224-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2008-01-24 US disclosed
US-7202264-B2 Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2007-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165547-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ILK, NOP2, PFAS ALDH1A1 4121/4885CACNA1B 3819/4885APBA1 105/4885
US-20080021224-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ILK, NOP2, PFAS ALDH1A1 4121/4885CACNA1B 3819/4885APBA1 105/4885
US-20100234528-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ILK, NOP2, PFAS ALDH1A1 4121/4885CACNA1B 3819/4885APBA1 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.